| Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study D Juric, J Rodon, AM Gonzalez-Angulo, HA Burris, J Bendell, JD Berlin, ... Cancer research 72 (8 Supplement), CT-01-CT-01, 2012 | 95 | 2012 |
| Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and … MA Loriot, J Ciccolini, F Thomas, C Barin-Le-Guellec, B Royer, G Milano, ... Bulletin du cancer 105 (4), 397-407, 2018 | 83 | 2018 |
| Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure A Schmitt, L Gladieff, CM Laffont, A Evrard, JC Boyer, A Lansiaux, ... Journal of Clinical Oncology 28 (30), 4568-4574, 2010 | 63 | 2010 |
| A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients A Schmitt, L Gladieff, A Lansiaux, C Bobin-Dubigeon, ... Clinical Cancer Research 15 (10), 3633-3639, 2009 | 53 | 2009 |
| 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer K Morawska, F Goirand, L Marceau, M Devaux, A Cueff, A Bertaut, ... Oncotarget 9 (14), 11559, 2018 | 48 | 2018 |
| Improved stability of lipiodol–drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using … M Boulin, A Schmitt, E Delhom, JP Cercueil, M Wendremaire, DC Imbs, ... European radiology 26 (2), 601-609, 2016 | 42 | 2016 |
| How can we best monitor 5-FU administration to maximize benefit to risk ratio? F Goirand, F Lemaitre, M Launay, C Tron, E Chatelut, JC Boyer, M Bardou, ... Expert opinion on drug metabolism & toxicology 14 (12), 1303-1313, 2018 | 40 | 2018 |
| A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma J Jolibois, A Schmitt, B Royer Journal of Chromatography B 1132, 121844, 2019 | 35 | 2019 |
| Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics B Guiu, A Schmitt, S Reinhardt, A Fohlen, T Pohl, M Wendremaire, ... Journal of Vascular and Interventional Radiology 26 (2), 262-270, 2015 | 35 | 2015 |
| Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients ML Pastor, CM Laffont, L Gladieff, A Schmitt, E Chatelut, D Concordet Pharmaceutical research 30 (11), 2795-2807, 2013 | 27 | 2013 |
| Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours H Rubie, B Geoerger, D Frappaz, A Schmitt, P Leblond, A Ndiaye, I Aerts, ... European Journal of Cancer 46 (15), 2763-2770, 2010 | 27 | 2010 |
| Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines: mise au point et recommandations nationales du … MA Loriot, J Ciccolini, F Thomas, C Barin-Le-Guellec, B Royer, G Milano, ... Bulletin du Cancer 105 (4), 397-407, 2018 | 23 | 2018 |
| Therapeutic drug monitoring as a tool to optimize 5-FU–based chemotherapy in gastrointestinal cancer patients older than 75 years P Macaire, K Morawska, J Vincent, V Quipourt, S Marilier, F Ghiringhelli, ... European Journal of Cancer 111, 116-125, 2019 | 21 | 2019 |
| Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination LC Mbatchi, A Schmitt, F Thomas, Y Cazaubon, J Robert, S Lumbroso, ... Pharmacogenomics 16 (13), 1439-1450, 2015 | 21 | 2015 |
| Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure M Dolat, P Macaire, F Goirand, J Vincent, A Hennequin, R Palmier, ... Pharmaceuticals 13 (11), 416, 2020 | 18 | 2020 |
| Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial B Guiu, JL Jouve, A Schmitt, A Minello, F Bonnetain, C Cassinotto, L Piron, ... Journal of hepatology 68 (6), 1163-1171, 2018 | 18 | 2018 |
| Standardization of Chemotherapy and Individual Dosing of Platinum Compounds F Puisset, A Schmitt, E Chatelut Anticancer research 34 (1), 465-470, 2014 | 15 | 2014 |
| Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation F Thomas, M Maillard, M Launay, C Tron, MC Etienne-Grimaldi, ... Annals of oncology: official journal of the European Society for Medical …, 2021 | 13 | 2021 |
| Suivi thérapeutique pharmacologique du 5-fluorouracile: mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer F Lemaitre, F Goirand, M Launay, E Chatelut, JC Boyer, A Evrard, ... Bulletin du Cancer 105 (9), 790-803, 2018 | 13 | 2018 |
| Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency M Maillard, M Launay, B Royer, J Guitton, E Gautier‐Veyret, S Broutin, ... British Journal of Clinical Pharmacology 89 (2), 762-772, 2023 | 9 | 2023 |
